Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 17/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14321088 | 0.85 | S1PR1 (0.44) | S1PR1S1PR5S1PR4 | |
| SCHEMBL2017781 | 0.85 | S1PR1 (0.44) | S1PR1S1PR5S1PR4 | |
| SCHEMBL950210 | 0.83 | S1PR1 (0.58) | S1PR1S1PR5S1PR4 | |
| SCHEMBL2020426 | 0.80 | S1PR1 (0.74) | S1PR1S1PR5S1PR4 | |
| SCHEMBL3429706 | 0.79 | S1PR1 (0.82) | S1PR1S1PR5S1PR4 | |
| SCHEMBL948657 | 0.79 | S1PR1 (0.40) | S1PR1S1PR5S1PR4 | |
| SCHEMBL948658 | 0.79 | S1PR1 (0.40) | S1PR1S1PR5S1PR4 | |
| SCHEMBL14321367 | 0.77 | S1PR1 (0.57) | S1PR1S1PR5S1PR4 | |
| SCHEMBL3428993 | 0.77 | S1PR1 (0.83) | S1PR1S1PR5S1PR4 | |
| SCHEMBL3429272 | 0.77 | S1PR1 (0.68) | S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252615-A1 | DIHYDRO- 1H- PYRROLO [1,2-A]INDOL-1-YL CARBOXYLIC DERIVATIVES WHICH ACT AS S1P1 AGONISTS | Arena Pharmaceuticals, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20100292233-A1 | DIHYDRO-1H-PYRROLO[1,2-A]INDOL-1-YL CARBOXYLIC ACID DERIVATIVES WHICH ACT AS S1P1 AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2009094157-A1 | DIHYDRO- 1H- PYRROLO [1,2-A] INDOL-1-YL CARBOXYLIC DERIVATIVES WHICH ACT AS S1P1 AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292233-A1 | DIHYDRO-1H-PYRROLO[1,2-A]INDOL-1-YL CARBOXYLIC ACID DERIVATIVES WHICH ACT AS S1P1 AGONISTS | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR5 4/4885DRD2 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.